Article
Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study.
Antiviral therapy - 1 Jan 2017
Lubel John, Strasser Simone, Stuart Katherine A, Dore Gregory, Thompson Alexander, Pianko Stephen, Bollipo Steven, Mitchell Joanne L, Fragomeli Vincenzo, Jones Tracey, Chivers Sarah, Gow Paul, Iser David, Levy Miriam, Tse Edmund, Gazzola Alessia, Cheng Wendy, Nazareth Saroj, Galhenage Sam, Wade Amanda, Weltman Martin, Wigg Alan, MacQuillan Gerry, Sasadeusz Joe, George Jacob, Zekry Amany, Roberts Stuart K
Abstract excerpt
BACKGROUND: Limited data exist on the outcomes of ritonavir-boosted paritaprevir with ombitasvir and dasabuvir (PrOD) ± ribavirin in a real-world setting. The aim of this study was to compare the efficacy and safety of PrOD-based therapy in hepatitis C genotype 1 patients with and without cirrhosis, and to explore pre-treatment factors predictive of sustained viral response (SVR) and serious adverse events (SAEs)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.